Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $122.50 Consensus PT from Analysts

Lantheus Holdings, Inc. (NASDAQ:LNTH) has earned a consensus rating of “Moderate Buy” from the eight analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $125.71.

A number of equities analysts recently commented on LNTH shares. Truist Financial reiterated a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. Redburn Atlantic started coverage on Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target for the company. JMP Securities reduced their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a report on Thursday, November 7th. Finally, StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st.

Institutional Investors Weigh In On Lantheus

A number of institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Lantheus by 5.6% during the first quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock worth $458,271,000 after acquiring an additional 389,828 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of Lantheus by 7.7% during the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock worth $393,844,000 after acquiring an additional 257,022 shares during the period. Farallon Capital Management LLC raised its position in shares of Lantheus by 53.7% in the second quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock valued at $182,999,000 after buying an additional 796,000 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Lantheus by 2.0% in the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after buying an additional 32,551 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Lantheus by 1.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock valued at $99,525,000 after buying an additional 19,071 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $89.27 on Monday. The stock has a market capitalization of $6.21 billion, a price-to-earnings ratio of 14.85 and a beta of 0.51. The business has a 50-day moving average of $101.76 and a 200-day moving average of $97.04. Lantheus has a fifty-two week low of $50.20 and a fifty-two week high of $126.89.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.